A Review on Neurotoxins from Clostridium botulinum against Neuro-muscular Disorders
Journal of Advances in Biology & Biotechnology,
Neuro-muscular disorders cause a series of serious complications in the human body, where some lead to considerable morbidity and mortality ocassionally. Neurological diseases result in dystrophy, inhibited growth, etc. This present review aimed to emphasize the employment of neurotoxins against neuro degenerative disorders. The source of neurotoxins includes botulinum (Clostridium botulinum), snakes like Vespa orientalis and some medically important arthropods like hornets and spiders. The review not only describes the potential of the neurotoxins in the treatment but also elucidates the mechanism of action of lethal toxins like botulinum. Safety and dosage regimens of various toxins with the help of proven study data would aid in endorsing researchers for further research on toxins making them more superior targeted drugs.
- Neuro-muscular Disorders
How to Cite
Kaat Desloovere, Guy Molenaers, Petra Pauwels, et al. Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Develop Med Child Neurol. 2007;49:56–61.
Miller F. Cerebral palsy, 3rd rd. New York: Springer; 2005.
Raina P, Santaguida P, Ismaila A, et al.. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Int Med. 2008;148:379-97.
Mukund H, Gawade SP. Evaluation of effects of photooxidized vespa orientalis venom on memory and learning in rats. J Ven Ani Tox incl Trop Dis. 2011;17:422-429.
Ram Kumar D, Manglesh Kumar S, Padma Singh, et al., Botulinum toxin: Bioweapon & magic drug. Ind J Med Res 2010; 132(5):489–503.
Marsh NA. Diagnostic uses of snake venom. Hemostasis. 2001;31:211-17.
Gawade SP, Prashar S. Pharmacody- namics of photooxidized echis carinatus venom product using UV sensitized methylene blue. Indian J Pharma Edu. 2004;38:81-5.
Reddy CM, Gawade SP. Evaluation of the effects of photo oxidised echis carinatus venom on learning, memory and stress. J Venom Anim Tox incl Trop Dis. 2006; 12:632-652.
Martins NM, Ferreira DA, Carvalho Rodrigues MA, et al.. Low-molecular-mass peptides from the venom of the amazonian viper bothrops atrox protect against brain mitochondrial swelling in rat: potential for neuroprotection. Toxicon. 2010;56:86-92.
Ishaya JS. Anticholinesterase-like activity by oriental hornet (vespa orientalis) venom and venom sac extract. Cell Mol Life Sci. 1979;35:636-639.
Graham Nicholson M, Andis Graudins. Spiders of medicinal importance in the asia pacific: atracotoxin, latrotoxin and related spider neurotoxins. Clin Exp Pharmacol Physio. 2002;29:785–794.
Van Ermengem E. Classics in infectious diseases. a new anaerobic bacillus and its relation to botulism. Rev Infect Dis. 1979; 4:701–719.
John Ney P, Kevin Joseph R. Neurologic uses of botulinum neurotoxin type A. Neuropsyc Dis and Treat 2007;3:785-798.
Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: Mechanisms of action. Arq Neuropsiquiatr. 2005;63:180–185.
Graham HK, Aoki KR, Auii-Rämö I, et al., Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67–79.
Ubhi T, Bhakta BB, Ives HL. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000;83: 481–487.
Molenaers G, Desloovere K, De Cat J. Single event multilevel botulinum toxin type A treatment and surgery: similarities and differences. Eur J Neurol. 2001;8:88–97.
Bottos M, Benedetti MG, Salucci P. Botulinum toxin with and without casting in ambulant children: a clinical and functional assessment. Dev Med Child Neurol. 2003; 45:758–762.
Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol. 2001;248:21–24.
Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102–7.
Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type a therapy for blepharospasm. Coch Data Syst Rev. 2005;1:CD004900.
Corry IS, Cosgrove AP, Walsh EG, et al. Botulinum toxin a in the hemiplegic upper limb: a double blind trial. Dev Med Child Neurol. 1997; 39:185–93.
Potulska A, Friedman A. Controlling sialorrhoea: a review of available treatment options. Exp Opin Pharmacother. 2005; 6:1551–4.
Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003; 61:1279–81.
Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg. 2007;33:76–80.
Borodic GE, Ferrante R, Pearce LB, et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum a toxin injections. Mov Disord. 1994;9:31–39.
Duchen LW, Strich SJ. The effects of botulinum toxin of the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol. 1968;53:84–89.
de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999; 96:3200–3205.
Flowers HH. The effects of X-irradiation on the biological activity of cotton moccasin (Anicistrodon Piscivorus) venom. Toxicon. 1963;1:131-136.
Bennacef- Heffar N., Laraba- Djebari F. Evaluation of the effect of gamma rays on the venom of vipera lebetina by biochemical study. Can J Physiol Pharmacol. 2003;81:1110-1117.
Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988;3:333–335.
Kristie B, Ross H, Cathy G, et al.. Botulinum toxin for spasticity in children with cerebral palsy: a omprehensive Evaluation. Pediatrics. 2007;120:49–58.
Jianjun L, Shurong J, Weihong W. Botulinum toxin-A with and without rehabilitation for the treatment of spastic cerebral palsy. J Int Med Res. 2013;0:1-6.
Bakheit AM, Thilmann AO, Ward AB. A Randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type a (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31:2402-2406.
Fry NR, Gough M, Shortland AP. Three-dimensional realisation of muscle morphology and architecture using ultrasound. Gait Posture. 2004;20:177–182.
Abstract View: 148 times
PDF Download: 46 times